The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Official Title: Expanded Access Use of Zanidatamab for the Treatment of HER2-Positive Advanced Solid Tumor
Study ID: NCT04578444
Brief Summary: This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
NoCo Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
TOI Clinical Research, Cerritos, California, United States
Salinas Valley Memorial Healthcare System, Salinas, California, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Jean Minjoz Hospital, Besançon, , France
Hopital Timone Marseille, Marseille cedex 5, , France
Hopital Haut-Leveque - CHU Bordeaux, Pessac, , France
Gustave Roussy Cancer Center, Villejuif, , France
ICCRS Candiolo, Candiolo, , Italy
Istituto Nazionale Tumori, Milano, , Italy
Istituto Clinico Humanitas, Milan, , Italy
Vall D'Hebron University Hospital, Barcelona, , Spain
Fundacion Jimenez Diaz University Hospital - Autonomous University of Madrid, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
The Princess Alexandra Hospital NHS Trust (Joanne Kwa, Pharmacist), Harlow, , United Kingdom
UCLH Cancer Institute (Meera Desai, Pharmacist), London, , United Kingdom
HCA Healthcare UK, London, , United Kingdom